← Oncology Approval Tracker

FDA DECISION ·

Enhertu

fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo

Traditional approvalTraditional conversionBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic HER2-positive breast cancer previously treated with a HER2-directed regimen in the metastatic setting, or recurring during or within six months after neoadjuvant or adjuvant HER2-directed treatment.

LAMPGEN ANALYSIS

Why it matters

This traditional approval also broadened eligibility to an earlier line or early recurrence after curative-intent treatment.

What research teams should watch

Verify the HER2 result and the timing and setting of prior HER2 therapy. Include pulmonary symptom triage in monitoring.

PRIMARY RECORDS

Sources